Related Experiment Video
Updated: May 13, 2026
07:26
Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T1)Magnetic Resonance Imaging
Published on: November 20, 2018
Gadolinium oxide nanoparticles as potential multimodal imaging and therapeutic agents
Tae Jeong Kim1, Kwon Seok Chae, Yongmin Chang
1Department of Applied Chemistry, College of Engineering, Kyungpook National University, Taegu 702-701, South Korea.
Current Topics in Medicinal Chemistry
|February 26, 2013
Summary
Hydrophilic gadolinium oxide nanoparticles serve as advanced multimodal imaging agents and drug carriers. These biocompatible nanoparticles offer superior T1 magnetic resonance imaging (MRI) contrast and potential for theranosis.
Area of Science:
- Nanotechnology
- Biomedical Imaging
- Materials Science
Background:
- Gadolinium oxide nanoparticles (Gd2O3 NPs) are explored for biomedical applications.
- Ligand coating enhances their biocompatibility and hydrophilic properties.
- Existing contrast agents have limitations in sensitivity and multimodal capabilities.
Purpose of the Study:
- To review the potential of ligand-coated gadolinium oxide nanoparticles.
- To highlight their applications as multimodal imaging agents, drug carriers, and therapeutic agents.
- To discuss their advantages over conventional agents.
Main Methods:
- Review of existing literature on gadolinium oxide nanoparticles.
- Analysis of their physicochemical properties and functionalization strategies.
- Evaluation of their performance in various imaging modalities and therapeutic applications.
Main Results:
- Gd2O3 NPs exhibit high r1 relaxivity for enhanced T1-weighted MRI contrast.
- They can be functionalized for multimodal imaging (FI, CT, PET, SPECT).
- Morphology modifications enable drug delivery; they also act as CT, USI contrast, and NCT agents.
Conclusions:
- Ligand-coated Gd2O3 NPs show significant promise as versatile theranostic agents.
- Their multimodal imaging capabilities and therapeutic potential offer advantages over current technologies.
- Targeted functionalization with antibodies or peptides can improve disease diagnosis and treatment efficacy.
